Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial

Boostrom, Ian, Bala, Yohan, Vasic, Jelena Minic, Gluvakov, Jelena, Chanard, Emmanuel, Barratt, Andrew H., Sands, Kirsty, Portal, Edward, Devigne, Laurence, Jones, Lucy C. ORCID: https://orcid.org/0000-0002-3872-4376 and Spiller, Owen B. ORCID: https://orcid.org/0000-0002-9117-6911 2021. Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial. Journal of Antimicrobial Chemotherapy 76 (12) , pp. 3175-3182. 10.1093/jac/dkab320

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (260kB)

Abstract

Objectives To evaluate the accuracy, susceptibility and specificity of MYCOPLASMA IST3, the next generation of the most popular culture-based in vitro diagnostic device designed to detect, identify and test the susceptibility of urogenital mycoplasma infections. Methods MYCOPLASMA IST3 was evaluated against culture- and molecular-based gold standard methodologies to detect, identify, enumerate and determine antimicrobial resistance for Mycoplasma hominis and Ureaplasma species in 516 clinical samples collected across France, Serbia and the UK. Sample types included vulvovaginal/endocervical or urethral swabs (dry swab or eSwab®), semen and urine samples, which included blinded analysis following addition of a panel of 80 characterized control strains. Results Overall species identification was excellent for both Ureaplasma spp. (98.4% sensitivity, 99.7% specificity) and M. hominis (95.7% sensitivity, 100% specificity) relative to combined colony morphology on agar and quantitative PCR standards. Non-dilution-based bacterial load estimation by the assay was accurate between 83.7% (M. hominis) and 86.3% (Ureaplasma spp.) of the time (increased to 94.2% and 100%, respectively, if ±10-fold variance was allowed) relative to colonies counted on agar. Resistance accuracy for Ureaplasma spp. varied from gold standards for only 11/605 of individual tests (major error rate = 1.8%) and for 14/917 individual tests for M. hominis (major error rate = 1.5%). Conclusions The redesigned MYCOPLASMA IST3 assay eliminated previous shortcomings by providing independent accurate resistance screening of M. hominis and Ureaplasma species, even in mixed infections, with CLSI-compliant thresholds. Specificity, sensitivity and enumeration estimates correlated closely with the confirmatory methods.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/)
Publisher:	Oxford University Press
ISSN:	0305-7453
Date of First Compliant Deposit:	23 September 2021
Date of Acceptance:	4 August 2021
Last Modified:	23 Jan 2024 09:40
URI:	https://orca.cardiff.ac.uk/id/eprint/144391

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item